Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reaching Asian markets

This article was originally published in The Tan Sheet

Executive Summary

Nutra Services International is a new service business formed "to help dietary supplement companies enter or improve sales performance in Asian markets" that will initially offer its services in Japan, South Korea, Taiwan and Indonesia, according to a June 20 announcement. The company's founders, Ken Roffe and Steve Hanson, both have launched and managed international brands such as Zila's Ester-C and Kemin's FloraGLO Lutein. "Our in-market management commitment allows companies with a desire to expand their sales activities into Asia...to do so without setting up their own international infrastructure," Hanson says. China is another Asian market that is garnering attention from the supplement industry (1"The Tan Sheet" May 1, 2006, p. 4)...

You may also be interested in...



China Is A Maze, Not A Wall For Direct Sellers; Be Prepared – Lawyer

Dietary supplement firms, including direct sellers, must have a local legal entity and manufacturing capabilities in China in order to distribute their products, Attorney Michael Chen stressed at a seminar for industry April 20

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel